Position in TENX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$3,879,844
+$3,342,134 QoQ
Shares Held
266,656
+693.0% QoQ
Ownership
0.713%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#34
of 111 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TENX Over Time
Shares Held
Position Value (USD)
Derivatives in TENX
reported options exposure · as of Jun 30, 2026CallValue
$2,042,820
CallShares
140,400
PutValue
$225,525
PutShares
15,500
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026JANE STREET GROUP, LLC holds $1,372,861,470 across 292 Biotechnology names. TENX ranks #40 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
2,934,193 | $218,538,693 | |
| 2 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
191,541 | $102,847,939 | |
| 3 | AXSM |
Axsome Therapeutics, Inc.
|
403,995 | $98,885,855 | |
| 4 | TGTX |
Tg Therapeutics, Inc.
|
1,752,646 | $96,290,370 | |
| 5 | EXEL |
Exelixis, Inc.
|
1,402,438 | $76,306,651 | |
| 6 | QURE |
uniQure N.V.
|
1,610,483 | $74,178,846 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
694,684 | $54,372,915 | |
| 8 | TVTX |
Travere Therapeutics, Inc.
|
938,699 | $53,327,489 |
All Filings in TENX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,879,844 | 266,656 | Shares | Defined | 2026-08-14 | |
| 2026-06-30 | $225,525 | 15,500 | Put | Defined | 2026-08-14 | |
| 2026-06-30 | $2,042,820 | 140,400 | Call | Defined | 2026-08-14 | |
| 2026-03-31 | $537,710 | 33,628 | Shares | Defined | 2026-05-12 | |
| No filing history on record for this holder in this stock. | ||||||